Balovaptan
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autism Spectrum Disorder
Conditions
Autism Spectrum Disorder
Trial Timeline
Dec 19, 2019 → May 6, 2020
NCT ID
NCT04049578About Balovaptan
Balovaptan is a phase 1 stage product being developed by Roche for Autism Spectrum Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT04049578. Target conditions include Autism Spectrum Disorder.
What happened to similar drugs?
0 of 10 similar drugs in Autism Spectrum Disorder were approved
Approved (0) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03912350 | Phase 1 | Withdrawn |
| NCT04049578 | Phase 1 | Terminated |
Competing Products
20 competing products in Autism Spectrum Disorder